Xmt-2056, a HER2-Targeted Immunosynthen Sting-Agonist Antibody-Drug Conjugate, Binds a Novel Epitope of HER2 and Shows Increased Anti-tumor Activity in Combination With Trastuzumab and Pertuzumab